Which studies does the NCCN recommend to establish a diagnosis of diffuse large B-cell lymphoma (DLBCL) non-Hodgkin lymphoma (NHL)?

Updated: Jun 12, 2019
  • Author: Priyank P Patel, MD; Chief Editor: Emmanuel C Besa, MD  more...
  • Print
Answer

Answer

In addition to its general guidance on diagnosis of lymphoma, the National Comprehensive Cancer Network (NCCN) recommends the following studies to establish a diagnosis of diffuse large B-cell lymphoma (DLBCL) [1] :

  • Immunohistochemistry (IHC) panel: CD20, CD3, CD5, CD10, CD45, BCL2, BCL6, Ki-67, IRF4/MUM1, MYC

  • Cell surface marker analysis by flow cytometry: kappa/lambda, CD45, CD3, CD5, CD19, CD10, CD20

  • Additional IHC panel for subtyping: Cyclin D1, kappa/lambda, CD30, CD138, EBER-ISH, ALK, HHV8

  • Fluorescence in situ hybridization (FISH) or cytogenetics for detection of t(14;18), t(3;v), t(8;14), t(8;v)


Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!